Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Jessica Merrill

New York, NY
Jessica Merrill is a Senior Editor for US Commercial Content for Informa’s pharmaceutical news publications, including “The Pink Sheet” and SCRIP. She has been covering the pharmaceutical industry as a journalist for more than 10 years, spanning the spectrum from R&D to regulatory to commercial. She was previously a reporter and editor for “The Pink Sheet” and “Pink Sheet” DAILY, specializing in business and commercial news, focusing largely on big pharma, M&A and business development, and the commercial landscape, including drug launches and market access. Before embarking on a career in healthcare journalism, she covered business news for the cosmetics industry and worked as a newspaper reporter.

Latest From Jessica Merrill

Radius Business Review Ends In Sale To Investment Funds

Gurnet Point Capital and Patient Square Capital will buy Radius Health for approximately $890m, including a contingent value right dependent on sales growth for osteoporosis drug Tymlos.

Deals Business Strategies

What Sanofi Early Research Chief Scientist Frank Nestle Is Most Excited About

Sanofi's Nestle talked to In Vivo about the company's early pipeline, the emerging technologies he thinks are most promising, and tapping external innovation.

New Science Leadership

Galapagos Enters Cancer Field With CellPoint Buy

Deal Snapshot: CEO Stoffels delivered on a recent promise to bring in mid-stage assets, acquiring a firm with a Phase I/IIa CAR-T therapy program for €125m ($131.6m) up front.

Deals Cancer

Lilly Olumiant Alopecia Launch Plans Focus On Disease Awareness And Coverage

Immunology president Patrik Jonsson talked to Scrip about being first to market with a systemic treatment for alopecia areata and launch plans for the new Olumiant indication.

Immune Disorders Dermatology

Optinose Looking For A Partner To Optimize Big Opportunity In Chronic Sinusitis

With positive Phase III data for its Xhance (fluticasone propionate) nasal spray in chronic sinusitis, Optinose believes it is poised to expand the target market for the drug 10-fold.

Ear, Nose & Throat Clinical Trials

Lilly's Olumiant Is First Drug FDA Approved For Alopecia Areata

The FDA approved baricitinib for the hair loss disorder despite safety concerns with JAK inhibitors. It carries the same warnings on risk of CV events and malignancy as the others in the class.

Approvals Immune Disorders
See All
UsernamePublicRestriction

Register